Navigation Links
Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
Date:7/30/2008

ents with heart failure. Results from Nile's Phase Ib and Phase IIa trials are expected to be available in 2008.

About CD-NP

CD-NP is a novel chimeric natriuretic peptide in clinical development for an initial indication of acute decompensated heart failure (ADHF). CD-NP was rationally designed by scientists at the Mayo Clinic's cardio-renal research labs. Current therapies for ADHF, including B-type natriuretic peptide, have been associated with favorable pharmacologic effects, but have also been associated with hypotension and decreased renal function which limit their utility in clinical practice. CD-NP was designed to preserve the favorable effects of current therapies while preventing or attenuating the hypotensive response, and enhancing or preserving renal function.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure; 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties; and CU-NP, a novel rationally designed natriuretic peptide. A key component of the company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at http://www.nilethera.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Nile's product development, fu
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... personalized immune therapies for operable and inoperable solid tumor cancers, ... at the 7 th Annual Phacilitate Immunotherapy Forum in ... presentation at Phacilitate will take place on January 26 at ...
(Date:1/23/2015)... 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is ... Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... fiduciary duties to shareholders. On January 21, ... reporting that Advaxis had misrepresented the clinical data for ...
(Date:1/23/2015)... TAMPA, Fla. , Jan. 23, 2015  iMD Companies, Inc. ... plan to increase market share and grab a foothold in ... with influence, production capabilities and a presence in the sector, ... them facilitate the growth of hemp and medical marijuana, iMD ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2
(Date:1/22/2015)... January 23, 2015 AngelWeddingDress, the premier ... 2015 maternity wedding dresses. View website of ... looking for maternity wedding dresses online for a bridal ... with high quality for them. Its maternity wedding dresses ...
(Date:1/22/2015)... January 22, 2015 A new white ... experience and person-centeredness in the long-term care environment as ... across the continuum. The paper, “The Power of Person-Centeredness ... perspectives and practices of the patient, resident and family ...
(Date:1/22/2015)... January 22, 2015 For over 20 years, Dr. ... Oceanside and Vista area has treated just about every type ... injury circumstances. And for those same twenty-plus years, the team ... all those injuries with the best possible doctor. With ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
(Date:1/22/2015)... 2015 IsoComforter, Inc. has introduced the most ... IsoTube design to treat specific body parts and muscle groups. ... and easy to use patented cold therapy machine with the ... orthopedic and muscle injuries. IsoComforter has become the industry ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... sales in the first half of Craneware,s 10th Anniversary YearATLANTA, Feb. ... improvement software for hospitals and health systems, is pleased to announce ... Highlights , , ... (H108: $12.9m) contributing to: , ...
... Hall to be Board Chairman; Siegrist Takes on Executive PostSOUTH ... announced his decision to transition from president and chief executive ... Inc., effective March 16. Rick Siegrist, M.B.A., president of a ... member of the Press Ganey Board of Directors, will take ...
... U.S. Department of Labor,s Occupational Safety and Health Administration ... Co., doing business as Ro-Corp Inc., for alleged willful, ... proposing more than $1.2 million in penalties for numerous ... the company,s facility in East St. Louis.OSHA began an ...
... The following was released today by SEIU UHW: NOTE TO ... expected to reach Congress--several hundred SEIU members from around the ... president,s vision to fix healthcare. The rally will be held at ... noon. California Healthcare for America Now (HCAN) ...
... disease severity, experts say, , , WEDNESDAY, Feb. 25 ... gene associated with cystic fibrosis. , Dr. Christopher ... and an international team of colleagues demonstrated that ... the airway disease that marks cystic fibrosis (CF) ...
... A newly released joint guideline produced by the American ... Association (AUA) recommends that healthy men who are screened ... the disease should talk to their doctors about using ... 5-ARIs lower the level of the hormone dihydrotestosterone (DHT), ...
Cached Medicine News:Health News:Craneware Announces Half-Year Results 2Health News:Changing of the Guard at Press Ganey 2Health News:Changing of the Guard at Press Ganey 3Health News:U.S. Department of Labor's OSHA proposes more than $1.2 million penalty to St. Louis area chemical repackaging and distribution company 2Health News:L.A. Area SEIU Members Gear Up to Support Effort to Fix Healthcare; Plan Rally for Thursday 2Health News:Study Pinpoints New Gene for Cystic Fibrosis 2Health News:Study Pinpoints New Gene for Cystic Fibrosis 3Health News:New ASCO/AUA guideline recommends men and their doctors discuss using 5-ARIs to reduce prostate cancer risk 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: